What early success did Zydus Lifesciences achieve?

Zydus Lifesciences scientists achieved an early success with an oral GLP-1 agonist, coded ZYOG1.

When did Zydus Lifesciences develop their GLP-1 agonist?

Zydus Lifesciences developed their GLP-1 agonist ZYOG1 approximately fifteen years before the current boom in obesity drugs.

What was the market focus for drug companies when Zydus developed ZYOG1?

When Zydus developed ZYOG1, many large companies were focused on research for anti-diabetes drugs, and obesity drugs had not yet made a significant impact.

Home / Science / Zydus: Early Pioneer in Obesity Drug Race

Zydus: Early Pioneer in Obesity Drug Race

4 Mar

•

Summary

Zydus scientists achieved early success with an oral GLP-1 agonist.
This development predates the current boom in popular obesity drugs.
The drug was coded ZYOG1, marking Zydus's innovative pipeline effort.

Fifteen years before the current surge in popularity for obesity drugs such as Ozempic and Mounjaro, Zydus Lifesciences had already achieved an early success. A group of scientists at the Indian pharmaceutical company developed an oral GLP-1 agonist, identified by the code ZYOG1.

This initiative was part of Zydus's ambitious strategy to build a pipeline of innovative drugs. At that time, the market impact of obesity drugs was not yet established, and many larger companies were concentrating their research efforts on anti-diabetes medications.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.